OSE Immunotherapeutics

Showing 2 posts of 2 posts found.

OSE Immunotherapies’ UC drug gets DSMB positive recommendation

July 6, 2023
Research and Development EMA, Gastrointestinal tract, OSE Immunotherapeutics, ulcerative colitis

French biotech company OSE Immunotherapeutics has announced that its Ulcerative Colitis (UC) trial’s Independent Drug Safety Monitoring Board (DSMB) has provided …

Boehringer teams up with OSE in €1.1 billion cancer drug partnership

April 5, 2018
Sales and Marketing Boehringer, Cancer, OSE Immunotherapeutics, partnership, pharma

Boehringer Ingelheim and biotech firm OSE Immunotherapeutics have announced that they have entered an exclusive collaboration and license agreement to …

Latest content